🇺🇸 FDA
Patent

US 9632074

Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition

granted A61KA61K31/337A61K31/437

Quick answer

US patent 9632074 (Compositions and methods for treating cancer and diseases and conditions responsive to cell growth inhibition) held by The Regents of the University of California expires Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/337, A61K31/437, A61K31/454, A61K31/496